Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer

Urology. 1996 Sep;48(3):357-64. doi: 10.1016/S0090-4295(96)00210-5.

Abstract

Objectives: Quantitative cytology by image-analysis techniques enables objective interpretation of nuclear features in light microscopic images. QUANTICYT, a quantitative karyometric cytology system, was used in the follow-up of patients with superficial bladder cancer.

Methods: From 1992 to 1995, 4137 samples from 1412 patients were obtained. At 1-year follow-up after the initial bladder washing, a tumor recurrence rate of 21% was found. In this period, tumor progression to invasive disease occurred in 1.6% of patients. Scoring of tumor by the QUANTICYT system was based on two nuclear features: the 2c deviation index and the mean of a nuclear shape feature: MPASS.

Results: The method was found to be reproducible and superior to visual cytologic interpretation. QUANTICYT analysis of the bladder washings resulted in a score of low, intermediate, and high risk. In a multivariate analysis, highest grade of earlier tumor and QUANTICYT risk score were the best predictors of tumor recurrence and progression. For the easy application of QUANTICYT analysis in daily routine, a report form that included patient history and DNA histogram was developed.

Conclusions: QUANTICYT karyometric analysis of bladder-wash material proved a useful, clinically applicable grading tool in the follow-up of patients with superficial bladder cancer, with sufficient power to be used in decision-making in the individual patient.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Intravesical
  • BCG Vaccine / administration & dosage
  • Carcinoma, Transitional Cell / pathology*
  • Carcinoma, Transitional Cell / therapy
  • Disease Progression
  • Equipment Design
  • Female
  • Follow-Up Studies
  • Humans
  • Karyometry* / instrumentation
  • Male
  • Multivariate Analysis
  • Neoplasm Recurrence, Local / epidemiology
  • Predictive Value of Tests
  • Prognosis
  • Reproducibility of Results
  • Urinary Bladder Neoplasms / pathology*
  • Urinary Bladder Neoplasms / therapy

Substances

  • BCG Vaccine